Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC

NCT05004831 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: fruquintinib plus TAS-102

Sponsor

Sun Yat-sen University